Compare · TBIO vs TXG
TBIO vs TXG
Side-by-side comparison of Telesis Bio Inc. (TBIO) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TBIO and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $9.43B, about 3.3x TBIO ($2.82B).
- TXG has hit the wire 6 times in the past 4 weeks while TBIO has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 4 for TBIO).
- Company
- Telesis Bio Inc.
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- $2.82B
- $9.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 6
- Recent ratings
- 4
- 25
Telesis Bio Inc.
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest TBIO
- Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
- Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
- SEC Form 15-12G filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
Latest TXG
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
- 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
- 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
- Argus initiated coverage on 10x Genomics with a new price target
- Director Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)
- Chief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)